BioSpace News Archive

In a campaign to screen drugs for the treatment of COVID-19, the disease caused by SARS-CoV-2, StoneWise, a company specialized in applying artificial intelligence to innovative drug design solutions for innovative drug R&D enterprises and institutions, has conducted research and been sharing the electronic structure data of more than 1400 nucleoside inhibitors against various RNA polymerases from patents up to February 5, 2020

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that company management will host a conference call & webcast to report topline results from DeCidE1, an ongoing Phase 2 study evaluating its lead compound, DPX-Survivac, in patients with advanced recurrent ovarian cancer

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the fourth quarter and full year 2019 financial results, provide an update on the company’s business, and discuss expectations for the future on Thursday, February 27, 2020

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference

LumaCyte, an advanced bioanalytical instrumentation company specializing in vaccine and cell and gene therapy bioprocess, production, and R&D analytical capabilities, announces its expansion into Europe with the establishment of LumaCyte, B.V. in The Netherlands.

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the full-year and fourth quarter ended December 31, 2019 and provided 2020 financial guidance.

Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has received an independent assessment of the absence of cardiotoxicity in patients treated with Annamycin in both its US and European open label and single arm Phase 1 clinical trials.

Lawrence Thompson, Chief Strategy and Revenue Officer at Advanced Medical Pricing Solutions (AMPS) has been selected to moderate the opening keynote, “Election 2020: The Future of Health Care in America,” on February 25, 2020, at the HCAA Executive Forum at the Wynn Hotel in Las Vegas, Nevada.